Vestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Vestal Point Capital LP boosted its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 23.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,000,000 shares of the biotechnology company's stock after purchasing an additional 750,000 shares during the quarter. Astria Therapeutics comprises approximately 3.3% of Vestal Point Capital LP's holdings, making the stock its 8th largest position. Vestal Point Capital LP owned about 7.09% of Astria Therapeutics worth $44,040,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company's stock valued at $35,693,000 after purchasing an additional 480,184 shares in the last quarter. Tidal Investments LLC acquired a new position in Astria Therapeutics in the first quarter valued at about $1,664,000. Sofinnova Investments Inc. bought a new stake in Astria Therapeutics during the second quarter worth about $552,000. ClariVest Asset Management LLC acquired a new stake in shares of Astria Therapeutics during the second quarter worth approximately $731,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Astria Therapeutics in the 2nd quarter worth approximately $6,142,000. Institutional investors own 98.98% of the company's stock.

Astria Therapeutics Stock Performance

ATXS traded down $0.11 during trading on Friday, reaching $10.39. 139,469 shares of the company's stock were exchanged, compared to its average volume of 601,783. The company's fifty day moving average price is $11.15 and its 200-day moving average price is $10.62. The firm has a market capitalization of $586.31 million, a PE ratio of -5.02 and a beta of 0.71. Astria Therapeutics, Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $16.90.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, November 14th. Oppenheimer increased their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.